SLC2A1 and cancer: WZB117, which binds to the GLUT1 at the exofacial sugar binding site, is a reversible competitive inhibitor of glucose uptake and exchange glucose transport (Ojelabi et al., 2016), and has now been shown to have therapeutic effects in cancer (Liu et al., 2012) and Plasmodium infection (Wei et al., 2018).